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Abstract
Brain amyloid burden may be quantitatively as-
sessed from positron emission tomography imag-
ing using standardised uptake value ratios. Us-
ing these ratios as an adjunct to visual image
assessment has been shown to improve inter-
reader reliability, however, the amyloid positiv-
ity threshold is dependent on the tracer and
specific image regions used to calculate the up-
take ratio. To address this problem, we propose
a machine learning approach to amyloid sta-
∗Corresponding author. Email address:
liam.cattell@eng.ox.ac.uk
†Data used in preparation of this article were ob-
tained from the Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI) database (adni.loni.usc.edu).As such, the
investigators within the ADNI contributed to the de-
sign and implementation of ADNI and/or provided
data but did not participate in analysis or writing
of this report. A complete listing of ADNI investi-
gators can be found at: http://adni.loni.usc.edu/wp-
content/uploads/how to apply/
ADNI Acknowledgemen List.pdf
tus classification, which is independent of tracer
and does not require a specific set of regions
of interest. Our method extracts feature vec-
tors from amyloid images, which are based on
histograms of oriented three-dimensional gradi-
ents. We optimised our method on 133 18F-
florbetapir brain volumes, and applied it to a
separate test set of 131 volumes. Using the same
parameter settings, we then applied our method
to 209 11C-PiB images and 128 18F-florbetaben
images. We compared our method to classifi-
cation results achieved using two other meth-
ods: standardised uptake value ratios and a ma-
chine learning method based on voxel intensi-
ties. Our method resulted in the largest mean
distances between the subjects and the classifi-
cation boundary, suggesting that it is less likely
to make low-confidence classification decisions.
Moreover, our method obtained the highest clas-
sification accuracy for all three tracers, and con-
sistently achieved above 96% accuracy.
Keywords Amyloid, Positron emission tomog-
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compound B, Classification
1 Introduction
Positron emission tomography (PET) is increas-
ingly used to assess the burden of fibrillar β-
amyloid in patients with suspected Alzheimer’s
disease (AD). Elevated levels of β-amyloid, in
the form of plaques, are a pathological biomarker
of the disease. The first tracer to specifi-
cally image these plaques in neuronal tissue was
11C-Pittsburgh Compound-B (11C-PiB) (Klunk
et al., 2004). Due to the short half-life of carbon-
11 (20 minutes), the compound needs to be pre-
pared on-site and used immediately. This re-
quires a cyclotron in the hospital, which is un-
common, and hence makes 11C-PiB impractical
for routine clinical use. More recently, several
other amyloid tracers have been developed using
the fluorine-18 isotope, which has a longer half-
life of 110 minutes and allows regional distribu-
tion. Three of these have recently been approved
by the US Food and Drug Administration (FDA)
for use in clinical diagnosis: 18F-florbetapir, 18F-
flutemetamol, and 18F-florbetaben (FDA, 2013,
2012; Piramal, 2014).
Prior to regulatory approval, the FDA and Eu-
ropean Medicines Association (EMA) gave much
attention to consistency of F-18 amyloid im-
age interpretation between readers (EMA Com-
mittee for Medicinal Products for Human Use,
2013; FDA Peripheral and Central Nervous Sys-
tem Drugs Advisory Committee, 2010). Con-
sequently, thorough reader training programmes
have been developed for visual interpretation.
However, as reported by Frey (2015), a lack of
concordance between independent readers sug-
gests the need for additional analytical ap-
proaches to clinical reading and reporting.
Brain amyloid burden can be evaluated quan-
titatively by calculating the ratio of tracer up-
take in a set of target brain regions to non-
specific tracer uptake in a reference region
(Barthel et al., 2011; Fleisher et al., 2011; Jack
et al., 2008; Jagust et al., 2009; Joshi et al., 2012;
Villemagne et al., 2011). This ratio is known
as the standardised uptake value ratio (SUVR).
Typically, the individual SUVRs for each target
region are averaged to form the mean, or com-
posite, SUVR (Rowe et al., 2008). It has been
shown that incorporating this ratio as an ad-
junct to the visual assessment of 18F-florbetapir
scans can decrease inter-reader variability (Nay-
ate et al., 2015; Pontecorvo et al., 2014).
The composite SUVR is usually used in a dis-
crete fashion, where subjects above a particu-
lar threshold are designated as amyloid posi-
tive, and subjects below a certain threshold are
designated as amyloid negative (Landau et al.,
2013). The thresholds are dependent on the
type of tracer, the brain regions used to calcu-
late the composite SUVR, and the delineation
of those regions. Examples of amyloid positiv-
ity thresholds and SUVR target and reference
regions are shown in Table 1. Although there is
a consensus in the literature about which gen-
eral brain areas are to be used in the composite
SUVR, there are differences in the details (Jack
et al., 2008; Jagust et al., 2009). In practice,
it means that for a specific tracer, the correct
set of regions and thresholds must be known
and applied. For example, since amyloid deposi-
tion does not typically occur in the cerebellum,
the reference regions presented in Table 1 are
all cerebellum-based. Nevertheless, Jack et al.
(2008) use the cerebellar grey matter, whereas
Joshi et al. (2012) use the whole cerebellum.
Moreover, the frontal lobe is a universal target
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region, but the delineation of the region varies
with the study; Barthel et al. (2011) use the
frontal lobe, whereas Villemagne et al. (2011)
use specific areas within the frontal lobe.
A method for amyloid status classification,
independent of SUVR, was proposed by Van-
denberghe et al. (2013). The authors classi-
fied 18F-flutemetamol scans as amyloid posi-
tive or amyloid negative using a machine learn-
ing method known as a support vector ma-
chine (SVM) (Cortes and Vapnik, 1995). The
SVM was trained using the voxel intensities, and
the leave-one-out testing method achieved 100%
agreement with the visual image assessments.
In this work, we propose an alternative ma-
chine learning method, which could serve as an
adjunct to visual image interpretation, like com-
posite SUVR, but without the need for defin-
ing tracer-specific regions of interest and select-
ing positivity thresholds. Our method trains an
SVM using features based on histograms of ori-
ented 3D gradients (3D HOG) rather than using
image intensity directly. The aim of this work
is therefore to compare the accuracy of amy-
loid status classification obtained using our new
method (3D HOG + SVM) with the intensity-
based SVM, and with the standard approach
based on SUVR. We show that our method can
be used across a range of amyloid tracers, with-
out the need to define different brain regions
or positivity thresholds; we trained our method
using 133 18F-florbetapir images and applied it
directly to 209 11C-PiB images and 128 18F-
florbetaben images with favourable results.
The rest of this paper is structured as fol-
lows: in Section 2 we present an overview of
the data and the preprocessing steps. Section
2 also introduces our proposed method of com-
bining 3D HOG with an SVM, and reviews both
the intensity-based SVM and SUVR methods.
In Section 3, we present the results for the three
classification methods, as well as detailing the
results of the 3D HOG optimisation process. Fi-
nally, in Section 4, we discuss the advantages of
our proposed method over the other two classi-
fication methods, and conclude this work.
2 Materials and Methods
2.1 Alzheimer’s Disease Neuroimag-
ing Initiative (ADNI) Data
Data used in the preparation of this article were
obtained from the ADNI database (adni.loni.
usc.edu). The ADNI was launched in 2003
by the National Institute on Aging (NIA), the
National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the US (FDA), private
pharmaceutical companies and non-profit orga-
nizations, as a $60 million, 5-year public-private
partnership. The primary goal of ADNI has been
to test whether serial magnetic resonance imag-
ing (MRI), PET, other biological markers, and
clinical and neuropsychological assessment can
be combined to measure the progression of mild
cognitive impairment (MCI) and early AD. De-
termination of sensitive and specific markers of
very early AD progression is intended to aid re-
searchers and clinicians to develop new treat-
ments and monitor their effectiveness, as well as
lessen the time and cost of clinical trials.
The Principal Investigator of this initiative
is Michael W. Weiner, M.D., VA Medical Cen-
ter and University of California, San Francisco.
ADNI is the result of efforts of many coinves-
tigators from a broad range of academic insti-
tutions and private corporations, and subjects
have been recruited from over 50 sites across the
USA and Canada. The initial goal of ADNI was
to recruit 800 subjects but ADNI has been fol-
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Table 1: Examples of the different regions used to calculate composite SUVRs for 11C-PiB, 18F-
florbetapir, and 18F-florbetaben. The regions and amyloid positive/negative threshold are specific
to each study.
Tracer Study Target regions Reference region Threshold
11C-PiB Jagust et al.
(2009)
anterior cingulate,
posterior cingu-
late/precuneus, pre-
frontal, lateral temporal,
parietal cortex
cerebellar grey mat-
ter
1.465
Jack et al.
(2008)
anterior cingulate, pre-
frontal, orbitofrontal,
parietal, posterior
cingulate/precuneus,
temporal
cerebellar grey mat-
ter
1.5
18F-florbetapir Fleisher et al.
(2011)
medial orbital frontal,
temporal, anterior cin-
gulate, posterior cingu-
late, parietal lobe, pre-
cuneus
cerebellum 1.17
Joshi et al.
(2012)
frontal, temporal, pari-
etal, anterior cingulate,
posterior cingulate, pre-
cuneus
whole cerebellum 1.10
18F-florbetaben Villemagne
et al. (2011)
dorsolateral prefrontal,
ventrolateral prefrontal,
orbitofrontal, supe-
rior parietal, lateral
temporal, lateral occip-
ital, anterior cingulate,
posterior cingulate
cerebellar cortex 1.4
Barthel et al.
(2011)
frontal, parietal, lateral
temporal, anterior cin-
gulate, posterior cingu-
late, occipital
cerebellar cortex 1.39
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lowed by ADNI-GO and ADNI-2. To date these
three protocols have recruited over 1,500 adults,
aged 55-90, to participate in the research, con-
sisting of cognitively normal older individuals,
people with early or late MCI and people with
early AD. The follow-up duration of each group
is specified in the protocols for ADNI-1, ADNI-2
and ADNI-GO. Subjects originally recruited for
ADNI-1 and ADNI-GO had the option to be fol-
lowed in ADNI-2. For up-to-date information,
see www.adni-info.org.
2.2 Data Acquisition and Pre-
Processing
18F-florbetapir PET and T1-weighted MR vol-
umes from 294 subjects were gathered from the
ADNI database. The two volumes for each sub-
ject selected for this study were acquired no
more than 12 months apart. Although the scans
were acquired at multiple sites, all sites followed
the same ADNI protocol1. For the purpose of
this work, the 18F-florbetapir PET volumes were
rigidly registered to their corresponding MR vol-
umes using Statistical Parametric Mapping, ver-
sion 82 (SPM8). The MR volumes were then
affinely registered to Montreal Neurological In-
stitute (MNI) space using FSL’s FLIRT software
(Jenkinson et al., 2002; Jenkinson and Smith,
2001), and the resulting transformations were
applied to the 18F-florbetapir volumes. Finally,
the MR and 18F-florbetapir images were skull-
stripped using a brain mask constructed from
MR tissue segmentations obtained using SPM8.
Prior to the classification experiments, the trans-
formed 18F-florbetapir PET brain volumes were
resampled to 2×2×2mm resolution. Axial slices
1http://adni.loni.usc.edu/wp-
content/uploads/2008/07/adni2-procedures-manual.pdf
2http://www.fil.ion.ucl.ac.uk/spm/software/spm8/
from examples of amyloid negative and amy-
loid positive 18F-florbetapir brain volumes, along
with their corresponding MR slices, are shown in
Figure 1(a).
In addition to the 18F-florbetapir data, 214
11C-PiB and corresponding T1-weighted MR
volumes were downloaded from the ADNI
database. The data belonged to 102 subjects,
but even though some subjects had multiple
scans (26 subjects had one scan, 42 subjects had
two scans, 32 subjects had three scans, and two
subjects had four scans), each 11C-PiB/MR pair
was treated independently. Each 11C-PiB vol-
ume and its corresponding MR volume were ac-
quired within 12 months of one another. Fur-
thermore, the 11C-PiB scans underwent the same
pre-processing as the 18F-florbetapir volumes.
Example amyloid positive and amyloid negative
axial slices from the 11C-PiB dataset are shown
in Figure 1(b).
The 18F-florbetaben PET volumes and cor-
responding T1-weighted MR volumes were pro-
vided from the phase 2A clinical trial of 18F-
florbetaben in 150 participants. The partici-
pant details and imaging protocols are all pro-
vided in Barthel et al. (2011). Seventeen sub-
jects were excluded due to severe image arte-
facts in the PET or MR images. The MR and
18F-florbetaben PET volumes were coregistered
using an in-house rigid registration algorithm.
The 18F-florbetaben images were then registered
to a PET template in MNI space using an in-
house affine registration algorithm and resam-
pled to 2×2×2mm resolution. The in-house rigid
and affine registration algorithms were imple-
mented using routines customised from Siemens
syngo.PET Amyloid Plaque (sPAP) quantifica-
tion software. The resulting transformations
were applied to the MR volumes. Analogously
to the 18F-florbetapir and 11C-PiB, a brain mask
5
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Negative Positive
(a) 18F-florbetapir
Negative Positive
(b) 11C-PiB
Negative Positive
(c) 18F-florbetaben
Figure 1: Axial slices from example amyloid negative (left) and amyloid positive (right) PET
volumes for (a) 18F-florbetapir, (b) 11C-PiB, and (c) 18F-florbetaben. The corresponding axial MR
slices are shown to the right of each PET image. These slices were selected after the PET and MR
volumes had been preprocessed.
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was constructed using tissue segmentations ob-
tained from SPM8. Both the 18F-florbetaben
PET volumes and their corresponding MR vol-
umes were skull-stripped. Figure 1(c) shows an
example axial slice for a 18F-florbetaben amy-
loid negative and 18F-florbetaben amyloid posi-
tive brain volume. The corresponding axial MR
slices are also shown in Figure 1(c).
2.3 Visual Assessment
In this study, the gold standard amyloid status
was determined for each subject using criteria
based on visual assessments from three image
readers. Data were excluded from the study if
the median rating was neither amyloid positive
nor amyloid negative. To interpret the PET
volumes as amyloid positive or amyloid nega-
tive, the three image readers (one clinical expert,
one senior neuro-PET researcher, and one ju-
nior PET image analysis researcher) interpreted
the images a total of six times. The junior re-
searcher assessed all of the images three times,
the senior neuro-PET researcher interpreted all
the images twice, and the clinical expert read all
of the images once. The tracers were assessed
one at a time (i.e all 18F-florbetapir scans were
interpreted before the 11C-PiB scans), but for
each tracer the images were presented in a ran-
dom order to prevent observer memory affecting
the assessments. Each reader was given instruc-
tions on how to display and interpret the im-
ages on a set of prearranged slices, without ac-
cess to the corresponding MR image. For the
18F-florbetapir and 18F-florbetaben scans, the
instructions were based on those provided by the
tracer manufacturers (Amyvid, 2012; NeuraCeq,
2014). The only major difference was the ad-
dition of an “equivocal” image class, for images
that did not clearly fulfil the definitions of posi-
tive or negative scans. Note that since the read-
ing instructions were very thorough, “equivocal”
was typically only selected when image quality
was particularly poor. The instructions for vi-
sual assessment of 11C-PiB were based on a com-
bination of those by Suotunen et al. (2010) and
Cohen et al. (2013). Again, an equivocal image
class was included for images that could not be
designated as either amyloid positive or amyloid
negative.
Using Fleiss’ kappa to assess the inter-
reader reliability, the six image interpretations
showed substantial agreement for all tracers
(18F-florbetapir: κ = 0.71, 11C-PiB: κ = 0.81,
18F-florbetaben: κ = 0.84). The gold standard
amyloid status was determined from the median
of the six image interpretations. Any images for
which the median interpretation was not amyloid
positive or amyloid negative were discarded. In
total, 30 18F-florbetapir images, five 11C-PiB im-
ages, and five 18F-florbetaben images were dis-
carded. The final 18F-florbetapir dataset com-
prised 264 subjects, the final 11C-PiB dataset
consisted of 209 subjects, and the final 18F-
florbetaben dataset contained 128 subjects. The
demographics of these are summarised in Table
2. It should be noted that although the inter-
reader agreement and number of equivocal scans
varies by tracer, this is not a reflection of the
tracers themselves. The discrepancies are pre-
dominantly due to differences in image quality
and the distributions of amyloid burden.
2.4 Image Analysis
In this work we compared three separate amyloid
classification methods: our method, which uses
histograms of oriented three-dimensional gradi-
ents as inputs to an SVM (3D HOG + SVM),
another SVM-based method using image inten-
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Table 2: Demographics of the amyloid positive (P) and amyloid negative (N) subjects used in this
study.
18F-florbetapir 11C-PiB 18F-florbetaben
P N P N P N
Count 149 115 167 42 53 75
Age ± std dev. 75.6± 7.6 74.7± 8.5 76.7± 7.6 76.1± 7.4 72.0± 7.9 69.0± 7.0
Sex (male/female) 84/65 60/55 103/64 27/15 27/26 35/40
sity directly, and SUVR. The three methods are
outlined in Sections 2.5-2.7.
2.5 Histogram of Oriented 3D Gradi-
ents (3D HOG)
2.5.1 Derivation of Feature Vectors
Image descriptors have been widely used in com-
puter vision to describe characteristics such as
texture, motion, and shapes in images and video
sequences (Belongie and Malik, 2000; Dalal and
Triggs, 2005; Lowe, 1999). Given a region of in-
terest, a descriptor represents the region as a fea-
ture vector. By applying machine learning tech-
niques to these feature vectors, they can be used
to detect objects in images. One such method,
histogram of oriented gradients (HOG), has been
used successfully to detect pedestrians in static
images (Dalal and Triggs, 2005). The image is
partitioned into a grid of uniformly spaced cells,
and the normalised histogram of image gradient
orientations in each cell forms the set of feature
vectors. An illustration of HOG in two dimen-
sions is shown in Figure 2. The key concepts
of this two-dimensional method were generalised
to three dimensions by Kla¨ser et al. (2008). Al-
though originally used for action recognition in
video volumes, we here propose to apply a sim-
ilar technique to PET volumes to classify brain
amyloid status.
In order to compute histograms of oriented
gradients across a PET volume, the volume is
partitioned into a uniform grid of cells ci of
size k × k × k voxels. Each cell is divided into
S × S × S sub-blocks bj , and for each sub-block
the mean gradient is computed. In the same
manner as Kla¨ser et al. (2008), we calculated
the mean gradient using a 3D extension of the
integral image (also known as a summed area
table), popularised by Viola and Jones (2001).
Given a volume v(x, y, z) and its gradient ∇v =
( ∂v
∂x
, ∂v
∂y
, ∂v
∂z
)T , the integral volume can be written
as:
I(x, y, z) =
∑
x′≤x,y′≤y,z′≤z
∇v(x′, y′, z′) (1)
The mean 3D gradient g¯ = (g¯x, g¯y, g¯z)
T within
a cuboid of size w × h × d at position (x, y, z)T
is then given by:
g¯ = (I(x+w, y + h, z + d)− I(x, y + h, z + d)
− I(x+ w, y, z + d) + I(x, y, z + d))
− (I(x+ w, y + h, z)− I(x, y + h, z)
− I(x+ w, y, z) + I(x, y, z)) (2)
Following computation of the 3D gradient g¯,
its orientation is quantised into a histogram with
8
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Figure 2: An illustration of 2D HOG features for an amyloid positive 18F-florbetapir axial slice
(top) and an amyloid negative 18F-florbetapir axial slice (middle). The bottom row shows the
general steps of the HOG algorithm: image gradients in a single cell (left), quantisation of those
gradients (centre), and the edge orientations associated with the histogram of gradients (right).
The intensity of edge orientations are determined from the magnitudes of the histogram bins. The
actual HOG features used in this work were computed in 3D, as described in Section 2.5.
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n discrete bins. A logical extension of the 2D
HOG method would be to use spherical polar
coordinates to quantise the 3D gradient orien-
tations. By dividing the elevation angle and az-
imuth into equally sized bins, gradients are quan-
tised using a similar system to latitude and lon-
gitude. However, this leads to problems at the
poles because the bins get progressively smaller.
This is demonstrated by the red circle in Figure
3(a).
We adopted the solution employed by Kla¨ser
et al. (2008), which used a regular polyhedron as
an approximation to a sphere. Rather than have
a continuous space of orientations, each side of
the polyhedron corresponds to a histogram bin.
In 3D space, there are only five polyhedra con-
structed from congruent regular polygons with
the same number of faces meeting at each ver-
tex. These polyhedra are known as Platonic
solids: tetrahedron, hexahedron (cube), octa-
hedron, dodecahedron, and icosahedron. They
have 4, 6, 8, 12, and 20 faces, respectively.
To quantise a 3D gradient g¯ with respect to its
orientation, g¯ is projected on to the axes going
through the origin of the coordinate system and
the centre of all faces of the polyhedron. Let-
ting P be the matrix of face centre coordinates
p1, . . . ,pn, the projection qˆ of g¯ is:
qˆ =
P · g¯
‖g¯‖2
(3)
Opposite gradient directions can be quantised
into the same histogram bin by halving the set of
face centre coordinates and taking the absolute
value of qˆ. Histograms organised in this manner
are said to have “half-orientation”.
Since g¯ should only vote in one histogram bin,
the projection qˆ is thresholded. The threshold
t = pTi ·pj is subtracted from qˆ and all negative
elements are set to zero. The magnitude of the
(a)
(b)
Figure 3: (a) Using spherical polar coordinates
to quantise the 3D gradients leads to problems
at the poles (red circle) because the bins get pro-
gressively smaller. (b) Therefore, we used a reg-
ular polyhedron as an approximation to a sphere
(Kla¨ser et al., 2008). The 3D gradients are pro-
jected on to the vectors from the centre of the
polyhedron to the centres of the faces.
10
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gradient is distributed according to the thresh-
olded projection qˆ′:
q =
‖g¯‖2· qˆ
′
‖qˆ′‖2
(4)
The histogram hci for a given cell ci is the
sum of the quantised mean gradients of the sub-
blocks qbj in that cell:
hci =
S3∑
j=1
qbj (5)
The histograms hci for each cell are concate-
nated over the S3 sub-blocks to form the final
feature vector for the entire volume.
2.5.2 Classification
A classifier is required to separate the feature
vectors associated with different image classes
(e.g. amyloid positive and amyloid negative).
Typically a support vector machine (SVM) is
used to classify HOG features (Dalal and Triggs,
2005; Kla¨ser et al., 2008). Using a set of correctly
labelled data, the SVM tries to find the hyper-
plane that maximises the margin between the
two classes. This hyperplane can then be used
to classify previously unseen data (often called
test data). Points on one side of the hyperplane
are classified as one class, and points on the other
side of the hyperplane belong to the other class.
In this work we used the SVM implementation
in the scikit-learn package for Python (Pedregosa
et al., 2011).
2.5.3 Parameter Optimisation
In order to determine the optimum parameters
for the 3D HOG method, the 18F-florbetapir
dataset was split into a training and test set. The
training set comprised 133 subjects (75 positive,
58 negative), and the test set consisted of 131
subjects (74 positive, 57 negative). All of the
18F-florbetapir classification results reported in
Section 3 were generated using the test set only.
To assess the generalisability of the method, no
3D HOG parameter optimisation was conducted
using the 11C-PiB and 18F-florbetaben data, so
the entire datasets were used for testing.
To optimise the parameters for the 3D HOG
feature descriptors, we computed feature vectors
from the 18F-florbetapir training set volumes for
a range of parameter values. Cell size ranged
from k = 4 voxels to k = 32 voxels in incre-
ments of 4 voxels, and the number of sub-blocks
S were in the set S = {1, 2, 4}. We also as-
sessed the number of histograms bins (dodecahe-
dron and icosahedron), and the effect of full- and
half-orientation. A comprehensive grid search of
parameters was conducted, resulting in 96 differ-
ent parameter combinations.
For each of the 3D HOG parameter combina-
tions, a SVM classifier was trained using the cor-
responding feature vectors of the 18F-florbetapir
training set. In order to ascertain the optimum
SVM parameters to use on the test data, we
performed ten-fold stratified cross-validation on
the training set. The training set was randomly
divided in to 10 subsets, each with the same
proportion of amyloid positve/negative subjects.
Nine subsets were used to train the SVM, and
the remaining subset was used as the validation
test dataset. This was repeated, such that each
subset was used as the test set. We used a SVM
with a Gaussian radial basis function (RBF) ker-
nel, and we optimised the slackness variable C
(where C = 10i for i = {−2, . . . , 3}) and the
free parameter of the RBF γ (where γ = 10i for
i = {−5, . . . , 2}) (Boser et al., 1992; Cortes and
Vapnik, 1995) using a grid search of parameters.
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2.5.4 Testing
The 3D HOG parameters and SVM parame-
ters that gave the highest classification accuracy,
sensitivity, and specificity on the 18F-florbetapir
training set were applied to the 18F-florbetapir
test set. These parameter values were also ap-
plied to the 11C-PiB and 18F-florbetaben data.
Leave-one-out testing was used to assess the per-
formance of the 3D HOG features for amyloid
status classification. For each fold, the SVM
was trained using all of the subjects except one.
The remaining subject was then used as the test
subject. This process was repeated until all of
the subjects had been used as the test subject.
Following leave-one-out testing for all three trac-
ers, we calculated the mean classification accu-
racy, sensitivity, and specificity. By adjusting
the SVM classifier’s decision boundary, receiver
operating characteristic (ROC) analysis was per-
formed on each of the tracers.
2.6 Standardised Uptake Value Ratio
2.6.1 Quantification Software
The ratio of tracer uptake in a set of target brain
regions to non-specific tracer uptake in a ref-
erence region, also known as SUVR, was com-
puted using the commercially available Siemens
syngo.PET Amyloid Plaque (sPAP) quantifica-
tion software. Prior to SUVR calculation, the
software automatically registers the subject’s
PET volume to a synthetic PET template, in
MNI space, in which the cortical regions of in-
terest are defined (Hutton et al., 2015; Peyrat
et al., 2012). The predefined set of six target re-
gions for 18F-florbetapir were: the frontal, pari-
etal, anterior cingulate, posterior cingulate, pre-
cuneus, and temporal lobes (Hutton et al., 2015).
The reference region was the whole cerebellum.
For 18F-florbetaben, slightly different predefined
target and reference regions were used (target re-
gions: frontal, parietal, anterior cingulate, pos-
terior cingulate, temporal, occipital lobes, ref-
erence: cerebellar cortex (Barthel et al., 2011)).
Note that the different tracers used different sets
of regions according to the published literature
(Hutton et al. (2015) and Barthel et al. (2011),
respectively).
The sPAP quantification method has been
validated for use with 18F-florbetapir and 18F-
florbetaben (Hutton et al., 2015, 2014; Peyrat
et al., 2012), but not for 11C-PiB because it is
not an FDA-approved tracer. However, it was
still possible to use sPAP for quantification of
the 11C-PiB data. Based on the literature by
Jagust et al. (2009) and Landau et al. (2013),
we calculated SUVRs using the 18F-florbetapir
target and reference regions.
During SUVR computation in sPAP, one 18F-
florbetapir volume, eight 18F-florbetaben vol-
umes, and three 11C-PiB volumes failed to ade-
quately register to the PET template. As a re-
sult, the registration was manually adjusted for
these subjects.
The composite SUVRs calculated using the
sPAP software were within the ranges reported
in the literature (Barthel et al., 2011; Fleisher
et al., 2011). For all three tracers, the mean
composite SUVR of the amyloid positive scans
was higher than the mean composite SUVR
of the amyloid negative scans (18F-florbetapir:
1.46±0.18 and 0.99±0.11, 11C-PiB: 1.62±0.46
and 1.01±0.13, and 18F-florbetaben: 1.73±0.22
and 1.25±0.11, respectively).
2.6.2 SUVR Analysis
Following the computation of composite SUVRs
for the 18F-florbetapir test dataset, classification
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results were obtained using an amyloid positiv-
ity threshold of SUVR > 1.12 (Hutton et al.,
2015). Similarly, classification results were ob-
tained from the 18F-florbetaben SUVRs using a
threshold of composite SUVR > 1.36 (Hutton
et al., 2014).
Since sPAP has not been validated for 11C-
PiB data, two regression equations were re-
quired to obtain an amyloid positivity thresh-
old that is appropriate for both the tracer and
the SUVR calculation method. Firstly, Landau
et al. (2013) provided a regression equation to
convert the 11C-PiB threshold tJagust from Ja-
gust et al. (2009) into a corresponding threshold
for the quantification method used by Joshi et al.
(2012):
tJoshi = 0.67tJagust + 0.15 (6)
where the subscript denotes the study from
which the threshold is acquired.
Hutton et al. (2015) also provided a regres-
sion equation to convert from the Joshi et al.
(2012) method threshold into an equivalent unit
for sPAP tsPAP:
tsPAP = 0.9782tJoshi + 0.04264 (7)
We can combine equations (6) and (7) to get
a final equation to convert between the 11C-PiB
threshold tJagust and sPAP tsPAP:
tsPAP = 0.9782(0.67tJagust + 0.15) + 0.04264
≃ 0.6554tJagust + 0.1894
(8)
By substituting tJagust = 1.465 (Jagust et al.,
2009) into equation (8), we get an equivalent
threshold for 11C-PiB in sPAP tsPAP = 1.15.
Consequently, following SUVR calculation in
sPAP, the accuracy of amyloid status classifi-
cation in 11C-PiB data was assessed using an
amyloid positivity threshold of composite SUVR
> 1.15.
2.7 Image Intensity
We compared our method and SUVR to the
machine learning method proposed by Vanden-
berghe et al. (2013). In that work, the authors
trained a SVM on voxel intensity to classify amy-
loid positivity in 18F-flutemetamol images. Each
image is a point in high-dimensional space, in
which each dimension is a voxel within the brain.
To reduce the dimension of the SVM, only vox-
els inside the brain were used. Once all of the
images were transformed into MNI space (see
Section 2.2), we constructed a brain mask us-
ing the linear MNI152 T1-weighted MR template
(Mazziotta et al., 2001). The mask was dilated
by 2mm to ensure that all of the registered PET
brains were wholly inside the mask. Prior to us-
ing the SVM, all of the images were normalised
to have zero mean and unit variance. The SVM
parameters were then optimised using the same
approach as in Section 2.5.3. The optimum pa-
rameters were applied to the 18F-florbetapir test
data, as well as the 11C-PiB and 18F-florbetaben
datasets. Leave-one-out testing was used to as-
sess the ability of the intensity-based SVMs to
classify amyloid status.
3 Results
3.1 3D HOG Parameter Optimisation
Figure 4 shows the best classification accuracies
achieved on the 18F-florbetapir training set for
each of the 96 3D HOG parameter combinations.
Each sub-plot relates to one of the four his-
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togram configurations (dodecahedron vs icosa-
hedron, and half-orientation vs full-orientation),
and shows the highest classification accuracy for
each cell size k (horizontal axis) and number
of sub-blocks S (vertical axis). A cell size of
k = 4 voxels universally resulted in the low-
est classification accuracy. However, 68 differ-
ent parameter combinations resulted in a mean
classification accuracy greater than 95%. Four
parameter combinations (highlighted in red in
Figure 4) achieved the same, highest classifica-
tion accuracy of 98.5%. However, one parame-
ter combination gave the highest combined clas-
sification accuracy, sensitivity, and specificity
(98.5%, 0.973, and 1.00, respectively) on the 18F-
florbetapir training set: cell size k = 16 voxels,
number of sub-blocks S = 1, icosahedron, half-
orientation histogram. This set of optimum 3D
HOG parameters was then applied to the 18F-
florbetapir test set, and the 11C-PiB and 18F-
florbetaben data.
3.2 Classification Results
The classification accuracy, sensitivity, speci-
ficity and area under the receiver operating char-
acteristic curve (AUC) for the 18F-florbetapir
test data are shown in Figure 5. The black
borders indicate the best results. The classifica-
tion results for the 11C-PiB and 18F-florbetaben
datasets are presented in Figures 6 and 7, re-
spectively. For all three tracers, the 3D HOG
+ SVM classification method resulted in the
largest classification accuracy (96.2%, 99.5%,
and 96.9%, respectively) and AUC (0.962, 0.988,
and 0.965, respectively). Using the DeLong
method (DeLong et al., 1988) to statistically
compare the AUCs of each classification method,
the 3D HOG + SVM method achieved a sig-
nificantly larger AUC than the intensity-SVM
method for 18F-florbetapir (p < 0.01). Further-
more, the 3D HOG + SVM classification method
also achieved a significantly larger AUC than
SUVR for 11C-PiB (p < 0.01). Although the 3D
HOG + SVM method had a larger AUC than
both the other methods for 18F-florbetaben, the
AUCs were not significantly different. For 18F-
florbetaben, the intensity-based SVM had the
same classification accuracy as the 3D HOG +
SVM method (96.9%). The 3D HOG + SVM
method had a higher specificity (0.965, 0.976,
and 0.987, respectively) than the SUVR method
(0.912, 0.881, and 0.867, respectively) across all
of the tracers tested. However, SUVR gave the
highest sensitivity for 18F-florbetapir and 18F-
florbetaben (0.973 and 0.962, respectively).
3.3 Distance to Classification Bound-
ary
Figures 8-10 show the distances of the test sub-
jects from their respective classification bound-
ary. For the SVM-based methods, the distances
are the Euclidean distances to the decision hy-
perplane. For the SUVR method, the distances
represent the subject’s SUVR minus the thresh-
old SUVR. The distances are normalised to the
maximum absolute distance from the boundary.
Smaller distances indicate a lower confidence in
the final classification decision. In Figures 8-
10, subjects in blue with positive distances were
incorrectly classified by the given classification
method. Similarly, subjects in red with negative
distances were also misclassified.
We used a two-sided t-test, corrected for two
comparisons, to examine whether the boundary
distances for the 3D HOG + SVM method were
significantly greater than the other two classifi-
cation methods. Values of p < 0.01 (p < 0.005,
corrected) are considered significant.
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Figure 4: The highest classification accuracies achieved for each of the 96 3D HOG parameter
combinations. Each sub-plot relates to one of the four histogram configurations (dodecahedron vs
icosahedron, and half-orientation vs full-orientation), and shows the highest classification accuracy
for each cell size k (horizontal axis) and number of sub-blocks S (vertical axis). Four parameter
combinations, highlighted in red, achieved the same, highest classification accuracy (98.5%).
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Figure 5: The classification accuracy, sensitivity, specificity and area under the receiver operating
characteristic curve (AUC) for the 18F-florbetapir test data. The best results are highlighted with
a black border.
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Figure 6: The classification accuracy, sensitivity, specificity and area under the receiver operating
characteristic curve (AUC) for the 11C-PiB test data. The best results are highlighted with a black
border.
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Figure 7: The classification accuracy, sensitivity, specificity and area under the receiver operating
characteristic curve (AUC) for the 18F-florbetaben data. The best results are highlighted with a
black border.
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Across all three tracers, the distances from the
boundary for the 3D HOG + SVM method were
found to be significantly greater than the dis-
tances of the SUVR method, for both amyloid
positive and amyloid negative subjects. Fur-
thermore, for both subject groups, the 18F-
florbetapir distances are significantly greater for
the 3D HOG + SVM method than the dis-
tances of the intensity-based SVM classification
method. The 3D HOG + SVM distances were
also significantly greater for the amyloid positive
18F-florbetaben subjects. In contrast, the dis-
tances for the amyloid positive 11C-PiB subjects
were significantly greater for the intensity-based
SVM method compared to the 3D HOG + SVM
method.
It is apparent from Figure 9 that one 11C-PiB
image was classified differently to the gold stan-
dard visual assessment by all three classification
methods (image #9). Similarly, in Figure 10,
18F-florbetaben image #104 was classified differ-
ently to the gold standard across all three meth-
ods. Axial slices from the PET and MR volumes
of these outliers are shown in Figure 11.
Although scans with equivocal visual reads
were eliminated from the three data sets prior
to classification analysis, we computed the nor-
malised distances of the equivocal scans from the
classification boundary for each automated clas-
sification method and tracer. The 3D HOG +
SVM method resulted in the largest mean ab-
solute distance for 18F-florbetapir (0.418), and
the intensity-based SVM achieved the largest
mean absolute distance for both 11C-PiB and
18F-florbetaben (0.878 and 0.700, respectively).
4 Discussion
4.1 Classification Accuracy
In this paper we have proposed an amyloid status
classification method that is independent of the
predefined regions of interest and amyloid posi-
tivity thresholds typically used to classify based
on SUVR. Our method has been shown to gen-
eralise across multiple tracers, and could be used
as an adjunct to visual interpretation of PET im-
ages, which is currently the standard method for
clinical assessment. In a clinical setting, it would
be straightforward to interpret the results due
to the method’s straightforward, binary output
(amyloid positive or amyloid negative). More-
over, unlike SUVR, knowledge of the specific
amyloid positivity thresholds for each tracer is
not required, and there is no need to check that
the target/reference regions are positioned cor-
rectly on the image.
Using visual assessment of the images as the
gold standard, the 3D HOG + SVM method re-
sulted in the highest classification accuracy and
AUC for all three of the tracers we evaluated.
This could be because it uses local intensity gra-
dients as features, rather than intensity directly.
Conceptually, this is similar to visual assessment
of 18F-florbetapir, which utilises local loss of con-
trast between adjacent grey and white matter,
and consequently, the 3D HOG + SVM method
is robust to spatially varying intensity levels.
This is advantageous in PET image classifica-
tion, when data acquired, and reconstructed, at
multiple sites and multiple scanners, may have
different spatially varying intensities. Moreover,
by quantising the gradients, the 3D HOG +
SVM method is more robust to noise than the
intensity-based SVM, which uses all of the vox-
els, which can include noise, as the feature vec-
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Figure 8: The normalised distances of 18F-florbetapir test subjects from the classification boundary.
Subjects in blue with positive distances were incorrectly classified by the given classification method.
Similarly, subjects in red with negative distances were also incorrectly classified. The dashed lines
indicate the mean distance from the boundary for the subjects visually designated as amyloid
positive and amyloid negative.
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Figure 9: The normalised distances of 11C-PiB test subjects from the classification boundary.
Subjects in blue with positive distances were incorrectly classified by the given classification method.
Similarly, subjects in red with negative distances were also incorrectly classified. The dashed lines
indicate the mean distance from the boundary for the subjects visually designated as amyloid
positive and amyloid negative.
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Figure 10: The normalised distances of 18F-florbetaben test subjects from the classification bound-
ary. Subjects in blue with positive distances were incorrectly classified by the given classification
method. Similarly, subjects in red with negative distances were also incorrectly classified. The
dashed lines indicate the mean distance from the boundary for the subjects visually designated as
amyloid positive and amyloid negative.
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(a) 11C-PiB, image #9
(b) 18F-florbetaben, image #104
Figure 11: PET and MR axial slices from the
two images which were classified differently to
the gold standard visual assessment by all three
classification methods. (a) 11C-PiB image #9
was visually assessed as amyloid negative, but
incorrectly classified as positive. However, on
closer inspection, tracer uptake was observed in
the frontal region (highlighted by the red box),
suggesting that the classification should be amy-
loid positive. (b) 18F-florbetaben image #104
was correctly assessed as positive, but automat-
ically classified as amyloid negative.
tor. It may be possible to achieve a higher classi-
fication accuracy with the intensity-based SVM
method by smoothing or downsampling the data
to reduce the noise.
Another reason for the high classification ac-
curacy and AUC of the 3D HOG + SVM method
could be the use of cells, instead of individual
voxels. As a result, 3D HOG can cope well with
minor misregistration of the brain to MNI space.
When calculating SUVRs, a small misalignment
of the PET brain could result in tracer uptake
appearing to be outside of the region of interest.
As a result, this may have some effect on SUVR.
For the 18F-florbetapir and 18F-florbetaben
tracers the SUVR classification method exhib-
ited the highest sensitivity. One reason for this
could be the nature of the amyloid positivity
thresholds. In a clinical setting, a test with a
high sensitivity will rarely misdiagnose a dis-
eased patient. Although false positives could
cause unnecessary worry or treatment, a false
negative patient could miss out on vital support
and care. However, this notion is merely specu-
lative, especially given that amyloid PET stud-
ies have generally not supported a clinically rel-
evant bias towards reporting a scan as positive,
and furthermore, there is currently no effective
treatment for Alzheimer’s disease.
In contrast, the results in Figure 6 show a rel-
atively lower classification accuracy (78.5%) and
sensitivity (0.760) for SUVR compared to the 3D
HOG + SVM and intensity-based SVM methods
in 11C-PiB cases. This could be due to the choice
of brain regions used to compute the SUVR, as
well as the amyloid positivity threshold. Since
11C-PiB has not been approved for clinical use,
the brain regions used to compute the 11C-PiB
SUVRs were taken from 18F-florbetapir litera-
ture. Moreover, the sPAP quantification soft-
ware that was used to calculate the SUVRs has
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not been validated with 11C-PiB data, so we
converted the amyloid positivity threshold from
Jagust et al. (2009) (1.465) to the sPAP scale
(1.15). Equation (8) was constructed from two
separate regression equations and implicitly as-
sumed that the SUVR behaves linearly between
the three quantification methods. In reality, this
assumption may not be true. Moreover, not only
could the original threshold of 1.465 be subop-
timal, but every conversion introduces rounding
errors. A slight change in the threshold can have
an effect on the classification results. For exam-
ple, by using a threshold of 1.16 instead of 1.15,
the classification accuracy decreases from 78.5%
to 78.0%. Similarly, the sensitivity decreases
from 0.760 to 0.754. Although these differences
appear small, on a large population a 0.5% differ-
ence in classification accuracy could mean sub-
stantial numbers of patients are misdiagnosed.
This result highlights the need for careful vali-
dation of new SUVR computation methods, and
amyloid positivity thresholds, for both existing
and new tracers, which is one of the goals of the
Centiloid Project (Klunk et al., 2015).
4.2 3D HOG Parameters
The results of the 3D HOG parameter optimi-
sation in Figure 4 suggest that this method is
likely to give high classification accuracy, even
with suboptimal parameters. This is confirmed
by the fact that 68 out of 96 parameter combina-
tions resulted in a classification accuracy greater
than 95%. Cell size k had the most profound
effect on classification accuracy, so very small or
very large values of k should not be used. In-
terestingly, the optimum number of subblocks
was S = 1. This is equivalent to not using
sub-blocks, and only calculating gradients in the
larger cells. One possible reason for this result
is that PET has a comparatively low resolution
compared to the video sequences for which 3D
HOG was designed. As a result, there is no need
to average gradients over numerous sub-blocks.
All four of the highest scoring parameter com-
binations used half-orientation histograms, sug-
gesting that the sign of the gradient is uninfor-
mative in this particular application. This seems
reasonable, given that the visual reading instruc-
tions for 18F-florbetaben state that the images
should be displayed in grey scale or inverse grey
scale (NeuraCeq, 2014).
4.3 Distance from the Classification
Boundary
For all cases except positive 11C-PiB subjects,
the 3D HOG + SVM method resulted in
the greatest mean distances from the decision
boundary. A large distance is desirable, since
points near the classification boundary represent
low-confidence classification decisions. Again,
one reason for the superior performance of the
3D HOG + SVMmethod could be that it utilises
image gradients, rather than direct voxel intensi-
ties. The resulting invariance to spatially vary-
ing intensity levels and noise robustness allows
the two populations to be more easily separated
than using SUVR or the intensity-based SVM
method.
The small distance between amyloid negative
subjects and the SUVR threshold supports its
relatively lower specificity in Figures 5-7. The
subjects close to the threshold are classified with
a lower confidence, and are more likely to be mis-
classified as false positives.
The two images that were classified differently
to the gold standard visual assessment (11C-PiB
image #9 and 18F-florbetaben image #104) were
visually assessed again by two of the original
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three readers. Although the 18F-florbetaben im-
age was again assessed to be an amyloid posi-
tive subject by the readers, the distance from
the classification boundary for the SUVR and 3D
HOG + SVM classification methods was small.
This indicates that the different automatic clas-
sification decision has low confidence, and that
this subject is a particularly difficult borderline
case. After visual reassessment of the 11C-PiB
case, for which the gold standard amyloid status
was negative, a small region of tracer uptake was
identified in the frontal lobe (highlighted by the
red box in Figure 11(a)), suggesting that the gold
standard amyloid status may have been incorrect
for this case. This highlights the importance of
using an adjunct to visual assessment of amyloid
images. In this study, the visual reads were con-
ducted using PET volumes only. However, using
MR images to help localise tracer uptake might
make visual assessment more robust.
In this study, scans were given an “equivocal”
visual assessment if they did not clearly fulfil the
stringent definitions of amyloid positive or amy-
loid negative scans. Typically, scans were only
designated as equivocal when readers lacked con-
fidence in a final classification due to poor im-
age quality. For this reason, equivocal scans are
the type of scans for which automated classifica-
tion could be most useful. Although there is no
gold standard to which the classification results
can be compared, the distances of the equivo-
cal scans from the boundary indicate the level
of confidence in the final classification of the au-
tomated classification methods. The 3D HOG
+ SVM method achieved the largest mean ab-
solute distance from the boundary (0.418) for
the equivocal 18F-florbetapir scans, suggesting
a higher level of confidence in the final clas-
sification than the SUVR and intensity-based
SVM methods. For the equivocal 11C-PiB and
18F-florbetaben scans, the intensity-based SVM
method resulted in the largest mean absolute
distance from the classification boundary (0.878
and 0.700, respectively). However, due to the
small sample size (only five equivocal scans for
both 11C-PiB and 18F-florbetaben), the dis-
tances for the intensity-based SVM method were
not significantly larger (p < 0.01) than those
achieved by the other two classification methods.
4.4 Methodological Considerations
In this study, the gold standard for amyloid sta-
tus was determined using criteria based on con-
sistent visual assessments from three image read-
ers. Although ADNI provides a clinical diag-
nosis (e.g. cognitively normal, mild cognitive
impairment, Alzheimer’s disease) for each sub-
ject at the time of the 18F-florbetapir and 11C-
PiB scans, these diagnoses are determined us-
ing a range of clinical tests. Consequently, the
visual interpretations of the scans may not cor-
relate with the clinical diagnoses (Frey, 2015).
For example, a subject with an amyloid nega-
tive scan may not be clinically diagnosed as a
healthy control. Since the methods employed
in this paper focus on classification of amyloid
status using PET images only, the clinical di-
agnoses from ADNI were discarded. Moreover,
the tracer manufacturer instructions state that
a positive 18F-florbetapir scan does not estab-
lish a diagnosis of Alzheimer’s disease or other
cognitive disorder (Amyvid, 2012).
For this study, the gold standard amyloid sta-
tus for each scan was obtained using the median
rating from six visual assessments by three dif-
ferent image readers. The most junior reader in-
terpreted the images three times and the most
senior reader assessed the images once. Al-
though the number of evaluations varied for each
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reader, this had little effect on the final gold
standard visual assessments and classification
experiments. For example, if the first assess-
ment from each reader were used, such that each
reader only contributed one data point per scan,
the gold standard classification would change for
only six 11C-PiB scans and two 18F-florbetaben
scans. The median visual assessment for both
18F-florbetaben scans would change from amy-
loid negative to equivocal, thus excluding the
scans from our study, and reducing the size of
the dataset. Similarly, four of the 11C-PiB scans
would be reclassified as equivocal scans. The me-
dian visual assessment of the remaining two 11C-
PiB scans would change from amyloid negative
to amyloid positive. Although the gold standard
classification would change for 17 18F-florbetapir
scans if the first visual assessment from each
reader were used, the median rating of all 17
scans would change to equivocal. Consequently,
these 17 scans would have been excluded from
this work, and therefore the effect on the classifi-
cation accuracies presented in Section 3.2 would
be minimal.
In this work, we optimised the 3D HOG pa-
rameters and SVM parameters completely inde-
pendently of the test data. We optimised the
3D HOG + SVM parameters using the 18F-
florbetapir training data, and used a leave-one-
out testing approach on the test data for all three
tracers. Since the 3D HOG + SVM parameters
were optimised using 18F-florbetapir data only,
the entire 11C-PiB and 18F-florbetaben data sets
were used for testing. Therefore, leave-one-out
testing was used so that the SVM classifier was
always trained using data from the same amy-
loid PET tracer as the test data. However, if the
SVM that is applied to the test data is trained
using the original 18F-florbetapir training data3,
the classification accuracies for the 3D HOG +
SVM method are only slightly lower than using
leave-one-out testing (18F-florbetapir: 90.8%,
11C-PiB: 96.7%, 18F-florbetaben: 93.8%). In
contrast, if the same approach is used to test
the intensity-based SVM method, the classifica-
tion accuracies are considerably lower than using
leave-one-out testing (18F-florbetapir: 56.5%,
11C-PiB: 79.9%, 18F-florbetaben: 41.4%).
In future, to fully assess the generalisability of
the 3D HOG + SVMmethod, we need to analyse
the classification results obtained by optimising
the 3D HOG parameters on other amyloid PET
tracers than 18F-florbetapir. This is the subject
of ongoing research, and for clarity, we chose not
to present our results here. Nevertheless, our
preliminary results indicate that the 3D HOG
+ SVM method can achieve a higher classifi-
cation accuracy than SUVR and the intensity-
based SVM method, regardless of the amyloid
PET tracer used to optimize the 3D HOG pa-
rameters.
Although we used all of the 11C-PiB and
18F-florbetaben data that were available to us,
the ADNI database contains many more 18F-
florbetapir scans than were used in this work.
Therefore, in future, it would be useful to test
our method on a larger dataset.
Prior to computing the 3D HOG feature vec-
tors, we affinely registered the PET volumes to
MNI space to ensure that the cells generally con-
tained the same brain regions across all sub-
jects. We could have used a deformable reg-
istration algorithm, however, to keep the pre-
processing steps of our method in line with
3i.e If a leave-one-out testing approach is not used, and
the SVM used to classify the 11C-PiB and 18F-florbetaben
data is trained using 18F-florbetapir data.
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the sPAP SUVR method, affine registration was
used. Furthermore, it has been shown that clas-
sification of Alzheimer’s disease patients versus
cognitively normal controls using SUVR is not
affected by the registration method (affine versus
deformable registration) (Cattell et al., 2015).
Many other feature descriptors have been de-
veloped in addition to histograms of oriented
gradients. For example, the Scale-Invariant Fea-
ture Transform (SIFT) algorithm has been suc-
cessfully used for object recognition in computer
vision tasks (Lowe, 1999), and has also been used
in feature-based morphometry in MRI to distin-
guish between patients with Alzheimer’s disease
and healthy controls (Toews et al., 2010). Nev-
ertheless, we chose to use 3D HOG features due
to their simplicity and speed of computation.
Moreover, unlike SIFT and Speeded Up Robust
Features (SURF) (Bay et al., 2006), HOG op-
erates on a dense grid of cells rather than indi-
vidual points of interest. A larger set of image
descriptors over a dense grid will typically offer
more information than similar descriptors eval-
uated at a sparse set of image points.
Unlike the original intensity-based SVM
method proposed by Vandenberghe et al. (2013),
which used a SVM with a linear kernel, we used
a SVM with a Gaussian radial basis function ker-
nel. Our primary reason for using a non-linear
kernel was because the subjects in the original
input space of the SVM might not be linearly
separable. Although a linear SVM is faster to
compute, and non-linear kernels can give rise
to overfitting, it has been shown that if com-
plete model selection using the Gaussian kernel
has been conducted, there is no need to consider
a linear SVM (Keerthi and Lin, 2003). In this
work, we optimised the parameters of the SVM
and Gaussian kernel on the 18F-florbetapir train-
ing data only, using a grid search of parameters.
On a practical level, our 3D HOG + SVM
method uses less memory than the intensity-
based SVM method. The 3D HOG feature vec-
tor comprised 1500 elements, whereas the fea-
ture vector for the intensity-based method con-
tained an element for each voxel inside the brain
mask (290409 elements in total). As the number
of elements increases, so does the time taken to
train the SVM. The SUVR is also very quick to
compute, but unlike our method, knowledge of
the underlying anatomy and disease pathology
is required in order to choose suitable target and
reference regions.
4.5 Conclusion
In this paper we have proposed a machine
learning method for amyloid status classifica-
tion based on histograms of oriented three-
dimensional gradients. We compared our
method to SUVRs obtained from clinically val-
idated amyloid quantification software, as well
as another machine learning method based
solely on image intensity (Vandenberghe et al.,
2013). Across three separate amyloid tracers,
our method achieved the highest classification
accuracy and area under the receiver operating
characteristic curve. Unlike SUVR, our 3D HOG
+ SVM method required very little recalibra-
tion between tracers, and we showed that our
method has the potential to produce satisfac-
tory results even with suboptimal parameters.
Moreover, the large separation between the pop-
ulation groups suggests that our method makes
fewer low-confidence classification decisions. In
addition, in the future, we plan to specify a band
of indecision on either side of the classification
boundary to give visual readers a measure of con-
fidence in the automatic classification, as well as
their own classification decision.
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Highlights 
· A machine learning approach to brain amyloid status classification is proposed. 
· The method is independent of PET tracer and requires little recalibration. 
· Classification accuracy was higher than SUVR for three amyloid tracers. 
